Literature DB >> 33520481

Propranolol and Weekly Paclitaxel in the Treatment of Metastatic Heart Angiosarcoma.

Oraianthi Fiste1, Apostolos Dimos2, Vasiliki-Elpida Kardara1, Konstantinos Ballasis1, Athanasios Karampeazis3.   

Abstract

Heart angiosarcoma, the most frequent among cardiac malignancies, is an extremely rare vascular tumor known to carry a dismal prognosis. The spectrum of presenting symptoms depends on tumor's size, its anatomic location, and its invasiveness, whereas imaging techniques including cardiac magnetic resonance are critical in the differential diagnosis between malignant and benign neoplasms. Despite there are various available systemic therapeutic regimens for advanced cardiac angiosarcomas, yet, it still remains unclear which of them offers the best survival outcome in general. We present the uncommon case of metastatic right atrium angiosarcoma in a young male patient, in which the combination of propranolol and weekly paclitaxel, as first-line treatment, showed promising activity with manageable toxicity. Given the existing strong rationale for repurposing propranolol in oncology, this therapeutic approach merits further investigation in prospective studies with heart angiosarcoma patients.
Copyright © 2020, Fiste et al.

Entities:  

Keywords:  cardiac neoplasms; heart angiosarcoma; propranolol; β-blockers

Year:  2020        PMID: 33520481      PMCID: PMC7834548          DOI: 10.7759/cureus.12262

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  1 in total

1.  Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?

Authors:  Alaa Embaby; Lisanne van Merendonk; Neeltje Steeghs; Jos Beijnen; Alwin Huitema
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.